SCHEMBL4693190

SCHEMBL4693190

Cc1ccc(-c2ccoc2C(=O)NC2CCN(CCC3(CCCC(=O)O)CCCCC3)CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
MCHR1 Q99705 3/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
TSHR P16473 2/20 0.35
HTT P42858 1/20 0.35
ATM Q13315 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
LMNA P02545 1/20 0.35
MAPK14 Q16539 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CNR1 P21554 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
S1PR1 P21453 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4691461 0.93 MCHR1 (0.38) L3MBTL1MCHR1ADRA1DADRA1AADRA1B
SCHEMBL4687466 0.92 L3MBTL1 (0.34) L3MBTL1MCHR1ADRA1DADRA1AADRA1B
SCHEMBL4687554 0.92 L3MBTL1 (0.38) L3MBTL1MCHR1TSHRSMN1; SMN2CARM1
SCHEMBL4688414 0.92 L3MBTL1 (0.37) L3MBTL1MCHR1ADRA1DADRA1AADRA1B
SCHEMBL4690432 0.91 MCHR1 (0.39) L3MBTL1MCHR1SMN1; SMN2CARM1PRMT6
SCHEMBL4688285 0.89 L3MBTL1 (0.36) L3MBTL1MCHR1CARM1PRMT6ALDH1A1
SCHEMBL5107097 0.89 L3MBTL1 (0.36) L3MBTL1MCHR1ADRA1ACARM1PRMT6
SCHEMBL4687447 0.88 PDE10A (0.39) L3MBTL1ADRA1DADRA1AADRA1BCARM1
SCHEMBL4686722 0.87 L3MBTL1 (0.36) L3MBTL1MCHR1TSHRCARM1PRMT6
SCHEMBL1848745 0.87 ALDH1A1 (0.41) L3MBTL1MCHR1ADRA1ASMN1; SMN2CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1443046-B1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME KYORIN SEIYAKU KK (JP) 2008-12-17 EP disclosed
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. 2008-08-14 US disclosed
US-7375115-B2 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-05-20 US disclosed
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 US disclosed
EP-1443046-A1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same CYP4F2, CYP1A2, CYP4B1 L3MBTL1 4882/4885MCHR1 1825/4885ADRA1D 670/4885
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same OPRM1, OPRD1, HRH4 L3MBTL1 3273/4885MCHR1 187/4885ADRA1D 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.